SynCore Biotechnology Co.,Ltd Stock

Equities

4192

TW0004192000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
47.8 TWD 0.00% Intraday chart for SynCore Biotechnology Co.,Ltd +1.06% +24.48%
Sales 2022 15.86M 487K Sales 2023 20.2M 620K Capitalization 1.35B 41.45M
Net income 2022 -189M -5.8M Net income 2023 -38M -1.17M EV / Sales 2022 171 x
Net cash position 2022 205M 6.28M Net cash position 2023 269M 8.27M EV / Sales 2023 53.5 x
P/E ratio 2022
-15.5 x
P/E ratio 2023
-32.2 x
Employees 40
Yield 2022 *
-
Yield 2023
-
Free-Float 30.7%
More Fundamentals * Assessed data
Dynamic Chart
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 week+1.06%
Current month+24.48%
1 month+27.64%
3 months+29.72%
6 months+13.81%
Current year+24.48%
More quotes
1 week
45.05
Extreme 45.05
47.95
1 month
37.60
Extreme 37.6
57.80
Current year
34.55
Extreme 34.55
57.80
1 year
34.55
Extreme 34.55
74.67
3 years
34.55
Extreme 34.55
550.22
5 years
34.55
Extreme 34.55
580.17
10 years
34.55
Extreme 34.55
580.17
More quotes
Managers TitleAgeSince
Chief Executive Officer - 08-06-08
Director of Finance/CFO - 13-05-31
Members of the board TitleAgeSince
Director/Board Member - 13-11-26
Founder - 08-06-25
Chief Executive Officer - 08-06-08
More insiders
Date Price Change Volume
24-04-25 47.8 0.00% 14,544
24-04-24 47.8 +5.05% 29,468
24-04-23 45.5 +0.22% 6,921
24-04-22 45.4 -2.99% 32,815
24-04-19 46.8 -1.06% 37,112

End-of-day quote Taipei Exchange, April 24, 2024

More quotes
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.
More about the company